Bifogade filer
Download announcement as PDF.pdf
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Informationsteknik |
| Industri | Programvara |
20.3.2025 17:02:40 CET | Monsenso | Company Announcement
Company announcement no. 02-2025
Copenhagen, 2025.03.20
This message includes inside information.
The Board of Directors has decided to grant warrants in the Company with the purpose of:
- Ensuring that shareholders and the Company's Executive Management have the same interests and that everyone makes a special effort for value creation.
- Retaining the Executive Management and employees of the Company.
Warrants will be granted according to § 5.3 of the company's articles of association.
Warrants granted to the Company's employees and Executive Management amount to 2,900,000 warrants which offer the right to subscribe for a nominal DKK 290,000 shares in the Company corresponding to 0,435 % of the Company’s total outstanding share capital.
The exercise price amounts to 0.25 DKK per warrant which corresponds to the market price calculated as a 30-day weighted average. The value of each warrant can be calculated at DKK 0.07 based on an interest rate of 5% p.a. and volatility of the company's shares of 10 % (using the Black-Scholes formula).
These warrants are granted as a one-time grant, and vesting is subject to the terms and conditions set by the Board of Directors where warrants vest with 1/36 per month from 1 May 2025 to and including 30 April 2028. Vesting is subject to the recipient´s employment in the Company at the time of vesting.
Warrants will be granted free of charge and can be exercised twice a year after publication of the Company's annual and semiannual report in an exercise window of 2 weeks. Warrants that are not exercised on 31 August 2032 will lapse.
Monsenso's share capital amounts to a nominal value of DKK 6,664,018.20 divided into 66,640,182 shares of DKK 0.10 each.
Any inquiries regarding this notice should be directed to:
Monsenso
CEO
Thomas Lethenborg
Tel +45 21 29 88 27
E-mail: lethenborg@monsenso.com
Chairman of the board
Peter Mørch Eriksen
E-mail: eriksen@monsenso.com
Certified Adviser:
HC Andersen Capital
Bredgade 23, 2
1264 København K
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com